Sacibertinib

N/A

Report date: 2025/05/12 15:59:02
NME

Base Information

Drug NameSacibertinib
Drug Alias NameHemay-022
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsEpidermal growth factor receptor erbB1 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsFoodborne DiseasesBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTianjin Hemay Pharmaceutical Co LtdXiajiang Hemei Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTianjin Hemay Bio-Tech Co LtdTianjin Hemay Oncology Pharmaceutical Co LtdTianjin Hemay Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsFoodborne Diseases

Other Information

ATC CodeN/A
Related LinksN/A